Droitwich Pharmacy acquired by MSA Global

In 2014, MSA Global Holdings acquired Droitwich Pharmacy — one of the largest independent dispensing chemists in the UK Midlands — in a competitive sale process advised by James Pugh on behalf of sole shareholder John Hinks.

The acquisition marked the first step in MSA Global's planned consolidation of community pharmacy assets in the UK and gave John a structured exit from a business he had built over more than three decades.

Overview of Droitwich Pharmacy

Founded in 1978, Droitwich Pharmacy grew over three and a half decades into one of the largest independent dispensing chemists in the Midlands, dispensing in excess of 20,000 prescriptions per month at the time of the sale.

The business had built a loyal patient base across Droitwich and the surrounding Worcestershire towns, supported by long-tenured pharmacy staff and a reputation for service that competed effectively with the national multiples.

By 2014, sole shareholder John Hinks was ready to plan a structured exit. James Pugh acted as sell-side M&A advisor to John throughout the process.

start your business sale planning today

Deal at a glance

Target	Droitwich Pharmacy
Acquirer	MSA Global Holdings
Completion date	2014
Deal value	Undisclosed
Deal structure	Share sale
Sell-side M&A advisor	James Pugh Now CapEQ
Buy-side legal advisor	Hawkins Hatton Corporate Lawyers
Sector	Community pharmacy (UK SIC G47.73)
Target HQ	Droitwich, Worcestershire
Founded	1978
Prescription volume at completion	20,000+ per month
Customer base	Local NHS patients across Droitwich and Worcestershire
Post-acquisition status	Integrated into MSA Global subsidiary Flintlow

Pharmacist at Droitwich Pharmacy dispensing counter, the year before the 2014 MSA Global sale

Strategic acquisition by MSA Global

MSA Global Holdings is a diversified healthcare group whose portfolio at the time of the transaction included Veenak International, GlobenGen, S&K Holdings, and the healthcare subsidiary Flintlow — into which Droitwich Pharmacy was integrated post-completion.

The acquisition was MSA's first move into community pharmacy and was conceived as the platform asset for a planned UK chemist consolidation strategy.

Hawkins Hatton Corporate Lawyers acted for the buyer; partner Colin Rodrigues led their team.

How the deal came together

The market backdrop

The UK community pharmacy market in 2014 sat at the early edge of a structural consolidation wave. NHS funding settlements were tightening, regulatory burden was rising, and the cost base of operating an independent dispensing chemist was beginning to drift upward faster than dispensing margin.

For independent owner-operators in their fifties and sixties, the question of how — and when — to exit was beginning to surface in earnest. The acquirer field was widening at the same time: large multiples, regional consolidators, and diversified healthcare groups were all assessing community pharmacy as a contracted-revenue asset class with defensible local market positions.

For a profitable, well-run independent like Droitwich Pharmacy, the conditions favoured a thorough sale process rather than a reactive response to the first inbound approach.

Finding the right acquirer

The mandate was to run a structured, competitive search rather than rely on the small number of acquirers John already knew of by name.

Buyers were identified across three groups: the established UK pharmacy multiples; regional independents looking to add scale; and diversified healthcare investors for whom community pharmacy represented a new platform sector. MSA Global Holdings came from the third group — a buyer with the strategic intent to use Droitwich as the first asset in a wider consolidation strategy, and the capital backing to support it.

Running a process that protected value

A wide initial outreach produced a deep field of credible interest. In the end, around 16 to 17 buyers were taken into commercial conversation, and 13 substantive offers were received and worked through with John.

The competitive tension that produced was material to the eventual price and structure — but it also created the harder problem of comparing offers that varied significantly in form, including share versus asset structures, deferred and contingent consideration, and the treatment of the freehold premises and lease assignments.

Working through that comparison in plain language with John was a central part of the advisory engagement. The eventual decision to progress with MSA Global was made on a clear-eyed view of price, structure, certainty of completion, and the buyer's plan for the business and its team.

Completing on the right terms

The transaction completed on terms that reflected the strength of the process and gave John a clean exit.

The Droitwich Pharmacy team and patient base transferred into MSA Global's Flintlow subsidiary; the dispensing operation continued without disruption to the patients who relied on it.

M&A advisory support

James Pugh acted as sell-side M&A advisor to John Hinks throughout the process, leading buyer identification, process management, offer comparison, negotiation, and completion.

James now leads sell-side mandates as a Partner at CapEQ — the M&A advisory firm he co-founded in 2020.

"From the first conversation through to completion and beyond, the priority was to give John the structure and the information he needed to make his own decisions with confidence — and to run a process that did justice to a business he had spent more than 30 years building." — James Pugh, Partner, CapEQ

more M&A - 15-strong pharmacy chain sold to private equity-backed group

CapEQ Partner James Pugh — sell-side M&A advisor for UK community pharmacy founders

About Droitwich Pharmacy

Founded in 1978, Droitwich Pharmacy was an independent community pharmacy serving Droitwich and the surrounding Worcestershire towns.

At the time of its 2014 sale to MSA Global, the business was one of the largest independent dispensing chemists in the Midlands by volume, dispensing more than 20,000 prescriptions per month, with a long-tenured team and a loyal local patient base.

About MSA Global Holdings

MSA Global Holdings is a diversified healthcare group whose portfolio at the time of the 2014 transaction included Veenak International, GlobenGen, S&K Holdings, and the healthcare subsidiary Flintlow.

The acquisition of Droitwich Pharmacy was the group's first move into UK community pharmacy ownership and was positioned as the platform asset for a planned consolidation strategy in the sector.

Client feedback

“During the time I was taken through the process by James Pugh, the deal leader who nursed me through every step of the way.

With James, we interviewed about 16 or 17 potential buyers and got 13 substantial offers.

In weeding out the offers, James’ advice was invaluable, as the deals offered were often quite complex to a simpleton like myself and the eventual buyer was chosen by considering several factors.

James nursed me through the whole process and even after the sale was completed he was still interested and indeed helped to resolve issues that had arisen.

All things considered I would thoroughly recommend James, who steered the project to a very successful conclusion.”

John Hinks, owner

Droitwich Pharmacy

Frequently asked questions

What acquirers value in UK community pharmacy M&A

Acquirers of UK community pharmacies typically value four things above all else: NHS dispensing contract continuity, monthly prescription volume and its mix between acute and repeat items, the quality of the patient relationship and location, and the strength of the dispensing team and superintendent pharmacist arrangements. A clean trading record under the Responsible Pharmacist regulations and a well-managed lease or freehold position will usually move the price further upward. Independent pharmacies with long-tenured staff, demonstrable patient loyalty, and clean financial reporting tend to attract a wider acquirer field — and a stronger competitive process.

Community pharmacy is an attractive platform asset for diversified healthcare investors because it combines a contracted NHS revenue stream, a defensible local market position, and limited cyclical exposure. For groups already operating in pharmaceutical wholesale, generic manufacture, or specialist services, owning a pharmacy estate creates margin capture along the supply chain and a direct channel to NHS patients. The acquisition of Droitwich Pharmacy by MSA Global Holdings — a group that already owned pharmaceutical wholesale and generics interests — followed exactly that thesis, with the pharmacy positioned as the first step in a wider consolidation plan.

UK pharmacy valuations are typically built from a combination of items dispensed per month, adjusted EBITDA, and a multiple range that varies with location, NHS contract status, and acquirer type. Strategic buyers — including multiples and consolidators — will often pay above the financial buyer benchmark where the pharmacy gives them geographic infill or scale advantage. Independent valuations need careful normalisation: locum costs, owner-operator remuneration, premises arrangements, and one-off purchasing benefits all need to be worked through before a defensible EBITDA figure can be presented to buyers. Running a competitive process gives the seller visibility on the range and reduces the risk of accepting an opening offer that anchors below the achievable price.

A structured competitive process tends to move three things in the seller's direction: price, deal structure, and certainty of completion. In the Droitwich Pharmacy sale, around 16 to 17 buyers entered commercial conversations and 13 went on to submit substantive offers. That field gave the seller real choice between share and asset structures, varying deferred consideration mechanics, and different post-completion involvement requirements — none of which would have surfaced as clearly in a single bilateral negotiation. Competitive tension also disciplines the eventual buyer's behaviour through diligence and to exchange.

Medium- and longer-term challenges for UK pharmacy founders

Useful preparation steps for any UK pharmacy owner thinking about exit are: get three years of trading accounts into clean, consistently presented form; normalise locum costs and any owner-operator drawings into a defensible EBITDA figure; document NHS dispensing contract terms and any active service contracts; confirm the position on premises (freehold, lease term, renewal options); and identify a clear plan for the superintendent pharmacist role under a change of ownership. Starting this work 12 to 18 months ahead of a planned sale gives an advisor the runway to position the business properly and run a process at the seller's pace rather than the buyer's.

The most common mistake is accepting the first inbound approach without running a wider process. Independent pharmacy owners are often contacted directly by local consolidators or by acquirer agents, and an early offer can feel like the right one because it arrives without effort. In practice, a single-buyer negotiation rarely produces the price, structure, or completion certainty available from a competitive field. The second most common mistake is starting the process too late — leaving no runway to normalise the accounts, document the NHS contract position, or address founder dependency before buyers begin diligence.

For most UK community pharmacy sales structured as share transactions, the NHS pharmaceutical services contract sits inside the company and transfers with it on completion, subject to NHS England (or devolved equivalent) notification requirements. For asset sales, the position is more involved — the acquirer typically needs to apply for the contract to be associated with the new ownership, and the timetable for this needs to be managed carefully alongside completion mechanics. Deal structure choice between share and asset routes has direct implications for contract continuity, tax treatment, and post-completion regulatory steps, and should be advised on early in the process.

A structured sell-side process for an independent UK pharmacy typically runs between 6 and 12 months from mandate to completion, with the shorter end of that range achievable for a single-site business with clean accounts and the longer end more typical of multi-site groups or those requiring more involved diligence on premises, locum arrangements, or contested NHS contract issues. Building that timeline into early planning — rather than starting the process under time pressure — is the difference between selling on the founder's terms and selling on the buyer's. A well-prepared single-site sale can complete inside nine months without compromising on price.

We'd love to hear your story

Let's talk about your future plans. Whether you're thinking about a sale now or starting to plan two or three years ahead, we can help you get clear on where your business journey is going.

book a chat with james